» Articles » PMID: 1434604

Implications of a Pre-existing Tumor Hypoxic Fraction on Photodynamic Therapy

Overview
Journal J Surg Res
Specialty General Surgery
Date 1992 Nov 1
PMID 1434604
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of oxygen in tissue is a requirement for photodynamic therapy (PDT)-induced destruction of solid tumors, otherwise no cell death occurs. Since many tumors have been shown to have significant populations of hypoxic cells, it is of clinical interest to determine if pre-existing tumor hypoxia limits phototherapy. This question was examined using RIF tumors where tumor response to PDT of completely oxygenated tumors was compared to tumors with an induced hypoxic fraction. Tumor hypoxia was induced by using vasoactive drugs (epinephrine, chlorpromazine, or isoproterenol), given 30 min prior to PDT, or by a surgical method. PDT consisted of 5 mg/kg Photofrin II ip 24 hr prior to treatment and 135 J/cm2 630-nm light. The administration of the various vasoactive agents induced hypoxic fractions of 2.2 to 10%. The surgical method induced hypoxic fractions of 35%. Tumor response and cure in animals given vasoactive agents did not differ from controls, suggesting that low levels of pre-existing tumor hypoxia do not limit photodynamic therapy in this tumor model. Animals with tumors made hypoxic by a surgical method showed significantly reduced tumor response to PDT. Only 14% of these animals had tumors which became flat and necrotic by the day following PDT, compared to nearly 100% for animals given vasoactive drugs or controls. Furthermore, no tumor cure was observed in animals treated by this method. The higher level of tumor hypoxia in these animals likely represents one point where large proportions of PDT-resistant cells can survive after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy.

Xu J, Shamul J, Kwizera E, He X Nanomaterials (Basel). 2022; 12(5).

PMID: 35269231 PMC: 8911864. DOI: 10.3390/nano12050743.


Photodynamic Therapy-Current Limitations and Novel Approaches.

Gunaydin G, Gedik M, Ayan S Front Chem. 2021; 9:691697.

PMID: 34178948 PMC: 8223074. DOI: 10.3389/fchem.2021.691697.


Achieving efficient photodynamic therapy under both normoxia and hypoxia using cyclometalated Ru(ii) photosensitizer through type I photochemical process.

Lv Z, Wei H, Li Q, Su X, Liu S, Yin Zhang K Chem Sci. 2018; 9(2):502-512.

PMID: 29619206 PMC: 5868078. DOI: 10.1039/c7sc03765a.


Transcriptional activation of HIF-1 by a ROS-ERK axis underlies the resistance to photodynamic therapy.

Lamberti M, Pansa M, Vera R, Fernandez-Zapico M, Rumie Vittar N, Rivarola V PLoS One. 2017; 12(5):e0177801.

PMID: 28545088 PMC: 5435305. DOI: 10.1371/journal.pone.0177801.


Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light.

Nani R, Gorka A, Nagaya T, Yamamoto T, Ivanic J, Kobayashi H ACS Cent Sci. 2017; 3(4):329-337.

PMID: 28470051 PMC: 5408340. DOI: 10.1021/acscentsci.7b00026.